Johnson Investment Counsel’s Jazz Pharmaceuticals JAZZ Stock Holding History

Johnson Investment Counsel’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36M	Sell	9,802 -7,779	-44%	-$1.7M	0.02%	305
2026 Q1	$3.32M	Buy	17,581 +87	+0.5%	+$15.2K	0.03%	221
2025 Q4	$2.97M	Sell	17,494 -3,660	-17%	-$561K	0.02%	238
2025 Q3	$2.79M	Buy	21,154 +319	+2%	+$38.3K	0.02%	248
2025 Q2	$2.21M	Buy	20,835 +45	+0.2%	+$4.89K	0.02%	284
2025 Q1	$2.58M	Buy	20,790 +1,000	+5%	+$130K	0.02%	242
2024 Q4	$2.44M	Sell	19,790 -1,100	-5%	-$130K	0.02%	244
2024 Q3	$2.33M	Buy	20,890 +160	+0.8%	+$17.5K	0.02%	256
2024 Q2	$2.21M	Buy	20,730 +3,890	+23%	+$428K	0.02%	254
2024 Q1	$2.03M	Buy	16,840 +4,444	+36%	+$544K	0.02%	271
2023 Q4	$1.52M	Sell	12,396 -700	-5%	-$87.4K	0.02%	303
2023 Q3	$1.7M	Buy	13,096 +110	+0.8%	+$14.7K	0.02%	273
2023 Q2	$1.61M	Buy	12,986 +2,646	+26%	+$356K	0.02%	283
2023 Q1	$1.51M	Buy	+10,340	New	+$1.53M	0.02%	283

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Johnson Investment Counsel's JAZZ Position: Q2 2026 in Review

Johnson Investment Counsel reduced its Jazz Pharmaceuticals (JAZZ) stake by 44% in Q2 2026, selling an estimated $1.7M and leaving 9,802 shares worth $2.36M. The position accounts for 0.02% of the portfolio, ranked #305.

Johnson Investment Counsel first reported a position in JAZZ in Q1 2023 and has held it in 14 quarters since. The position peaked at $3.32M in Q1 2026. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Johnson Investment Counsel held 9,802 shares of Jazz Pharmaceuticals worth $2.36M as of Q2 2026.
Johnson Investment Counsel sold 7,779 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.7M.
Jazz Pharmaceuticals made up 0.02% of Johnson Investment Counsel's portfolio in Q2 2026, its #305 holding.
Johnson Investment Counsel first reported a position in Jazz Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Johnson Investment Counsel's Jazz Pharmaceuticals position peaked at $3.32M in Q1 2026.
647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.